U.K. life sciences company Abcam has expanded its presence in rabbit monoclonal antibodies with the acquisition of California’s Calico Biolabs for an undisclosed price.
Calico develops custom high-quality recombinant rabbit monoclonal antibodies for diagnostic and biopharmaceutical companies. With the deal, Abcam gets Calico’s catalog of ready-made CAL antibodies for immunohistochemistry as well as its custom development services.
“This acquisition significantly expands our leadership in recombinant rabbit monoclonal antibody technology,” Joyce Young, an Abcam vice president, said in a statement. “The combination of our complementary antibody engineering capabilities will further support our mission to provide our customers with access to the best antibodies for both today’s and tomorrow’s targets of interest.”
Last year, Abcam made a run at gene editing specialist Horizon Discovery for a deal that would have been worth $367 million. However, Horizon rejected the offer and instead of sweetening the deal Abcam hit the pause button on the move.